Name: Jiade Jay Lu
Academic Title: PhD
Position: Chair Professor
Email: lujiade@hyhospital.com
Address: Medical Building 402-2222, North District of Dushu Lake Campus
Contact Phone: +86 512 65884829
Ⅰ、Educational and Professional Experience
1、Educational Background：
2003.03–2005.12 University of California, Los Angeles (UCLA, USA) & National University of Singapore Business School (NUS, Singapore), Master of Business Administration (MBA, Joint Program)
1992.09–1996.06 State University of New York at Buffalo (USA), Doctor of Medicine (MD)
1988.08–1992.09 State University of New York at Buffalo (USA), Bachelor of Science in Biochemistry
2、Professional Experience：
2022.03–Present Guangdong Meihe Healthcare Management Co., Ltd., Vice President, Director of Oncology Center, Head of Proton & Heavy Ion Center
2014.02–2022.02 Shanghai Proton and Heavy Ion Center, Executive Vice President; Fudan University, Professor
2001.09–2014.02 National University Hospital, Singapore, Head, Department of Radiation Oncology; National University of Singapore, Vice Dean (Research)
1997.07–2001.07 Jackson Memorial Hospital, Resident & Fellow Physician
1996.07–1997.05 Buffalo Sisters Hospital, Resident Physician
Ⅱ、Research Focus
1、Precision and Accurate Radiotherapy for Tumors
2、Proton and Heavy Ion Therapy Technology and Clinical Practice
3、Multidisciplinary Comprehensive Treatment for Head & Neck and Central Nervous System Tumors
4、Development and International Promotion of Clinical Guidelines for Particle Therapy
Ⅲ、Project/Honor/Award
1. Shanghai Magnolia Silver Award, for outstanding contributions to the management of SPHIC, international collaboration, and the development/application of proton/heavy ion radiotherapy technology (2020)
2. Shanghai Outstanding Academic/Technology Leader, awarded by Shanghai Science and Technology Commission (2019)
3. Zhangjiang Outstanding Innovation and Entrepreneurship Talent Award, Shanghai (2018)
4. Shanghai Magnolia Memorial Award, for contributions to SPHIC management and particle therapy technology development/application (2017)
5. "Science Chinese" Person of the Year (2016)
6. National "Thousand Talents Plan" Distinguished Professor (11th Batch, 2015); Shanghai "Thousand Talents Plan" Distinguished Professor (4th Batch, 2014)
7. Shanghai International Science and Technology Cooperation Award (2013)
8. Radiological Society of North America (RSNA) Roentgen Resident/Fellow Research Award (2001)
9. National Key R&D Program of China "Research and Development of Digital Diagnostic and Therapeutic Equipment" Project: Research and clinical implementation of multi-beam precision radiotherapy planning technology for hypoxic tumors guided by molecular imaging (Project No. 2018YFC0115700). Funding: 10.285 million RMB. Period: Aug 2018 -- Jul 2021 (Completed). Role: Principal Investigator.
Ⅳ、Academic Part-time Roles & Student Guidance Outcomes
1. Vice President, Shanghai Overseas Friendship Association
2. Principal Investigator and Chief Scientist, National Key R&D Program of China (2018-2022)
3. Series Editor for "Medical Radiology: Radiation Oncology" and "Practical Guideline in Radiation Oncology" (Springer Publishing, globally distributed). These are currently the only two series of books worldwide dedicated to Radiation Oncology.
4. Editorial Roles: Editor-in-Chief: Journal of Radiation Oncology (Springer), Chinese Clinical Oncology (AME)
5. Associate Editor: Asia-Pacific Journal of Clinical Oncology
6. Editorial Board Member: Chinese Journal of Cancer Research (AME), Translational Cancer Research (AME), Cancer Medicine, Journal of Thoracic Disease (AME), Chinese Journal of Clinical Oncology
7. Former Academic Advisor and Independent Non-Executive Director for multinational corporations including ELSEVIER, Excerpta Medica, and Healthway Medical.
8. Honorary Chairman, Proton and Heavy Ion Therapy Committee, China Health Science and Technology Promotion Society
Ⅴ、Recent Five-Year Representative Research Outcomes
1. Ding Q, Wang C, Zhang Z, Liao J, Tang L, Lu JJ*, Tan Z*. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Transl Lung Cancer R. 2025;14(6):2011–2030.
2. Hu J, Huang Q, Hu W, Liang F, Gao J, Yang J, Qiu X, Zhang H, Zhang G, Lu JJ*, Kong L*. Tumor volume instead of recurrent T category predicts clinical outcome of patients with locally recurrent nasopharyngeal carcinoma salvaged by carbon ion radiation therapy. Oral Oncol. 2024;151:106683.
3. Liu W, Chen L, Zhang H, Qiu X, Huang Q, Wan F, Le Z, Geng S, Zhang A, Qiu S, Chen L, Kong L*, Lu JJ*. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nat Commun. 2023;14(1):265.
4. Huang Y, Huang Q, Huang Z, Gao J, Hu J, Hu W, Yang J, Qiu X, Zhang W, Kong L*, Lu JJ*. In vitro evaluation of photon and carbon ion radiotherapy in combination with cisplatin in head and neck squamous cell carcinoma cell lines. Front Oncol. 2023;13:1148920.
5. Hu W, Huang Q, Hu J, Gao J, Yang J, Qiu X, Zhang W, Kong L*, Lu JJ*. Preliminary clinical outcomes of head and neck squamous cell carcinoma treated with particle beam radiation therapy. Cancer Med. 2023;12(12):13538–13549.
6. Huang Q, Huang Y, Gao J, Hu J, Hu W, Yang J, Qiu X, Zhang W, Kong L*, Lu JJ*. Carbon ion radiotherapy combined with immunotherapy: Synergistic anti-tumor efficacy and preliminary investigation of ferroptosis. Cancer Immunol Immunother. 2023;72(12):4077–4088.
7. Hu J, Huang Q, Hu W, Gao J, Yang J, Qiu X, Zhang W, Kong L*, Lu JJ*. A protocol for a randomized trial evaluating the role of carbon-ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma. Cancer Med. 2023;12(22):23347–23357.
8. Guan X, Huang Q, Hu W, Hu J, Yang J, Qiu X, Gao J, Zhang W, Kong L*, Lu JJ*. Feasibility of lattice radiotherapy using proton and carbon-ion pencil beam for sinonasal malignancy. Ann Transl Med. 2022;10(8):461.
9. Zhang Y, Li P, Hu J, Hu W, Yang J, Qiu X, Gao J, Kong L*, Lu JJ*. Identification of molecular subtypes based on inflammatory response in lower-grade glioma. Inflamm Regen. 2022;42(1):29.
10. Huang Q, Zhang W, Hu W, Hu J, Gao J, Yang J, Qiu X, Kong L*, Lu JJ*. Multi-omics data analyses identify B7-H3 as a novel prognostic biomarker and predict response to immune checkpoint blockade in head and neck squamous cell carcinoma. Front Immunol. 2021;12:616985.